Literatur zum Artikel
Studien als Grundlage zur Einführung der Diabeteschirurgie

1. Linder R, Ahrens S, Koppel D, et al (2011) The benefit and efficiency of the disease management program for type 2 diabetes. Dtsch Ärztebl Int 108: 155–162
2. Rathmann W, Haastert B, Icks A, et al (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46: 182–189
3. Tesfaye S, Stevens LK, Stephenson JM, et al (1996) Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia. 39: 1377–1384
4. Wu Z, Cheng Y, Aung LH, Li B (2013) Association between adiponectin concentrations and cardiovascular disease in diabetic patients: a systematic review and meta-analysis. PLoS One 8(11): e78485
5. Meigs JB, Rutter MK, Sullivan LM, et al (2007) Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 30: 1219–1225
6. Rutter MK, Meigs JB, Sullivan LM, et al (2005) Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 54: 3252–3257
7. Alva ML, Gray A, Mihaylova B, et al (2015) The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabetic Med 32: 459–466
8. American Diabetes Association (2013) Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36: 1033-1046
9. Nichols GA, Vupputuri S, Lau H (2011) Medical care costs associated with progression of diabetic nephropathy. Diabetes Care 34: 2374–2378
10. Schaufler TM, Wolff M (2010) Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy 8: 191–202
11. Look ARG, Wing RR, Bolin P, et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369: 145–154
12. O'Connor PJ, Ismail-Beigi F (2011) Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE. Ther Adv Endocrinol Metab 2: 17–26
13. Ismail-Beigi F, Craven T, Banerji MA, et al (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376(9739): 419–430
14. Singh T, Kochhar GS, Goh GB, et al (2017) Safety and efficacy of bariatric surgery in patients with advanced fibrosis. Int J Obes (Lond) 41: 443–449
15. Dluhy RG, McMahon GT (2008) Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358: 2630–2633
16. Alvarez Guisasola F, Mavros P, Nocea G, et al (2008) Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 10 (Suppl 1): 8–15
17. Hemmingsen B, Lund SS, Gluud C, et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343: d6898
18. Zinman B, Wanner C, Lachin JM, et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128
19. Marso SP, Daniels GH, Brown-Frandsen K, et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375: 311–322
20. Chen Y, Corsino L, Shantavasinkul PC, et al (2016) Gastric bypass surgery leads to long-term remission or improvement of type 2 diabetes and significant decrease of microvascular and macrovascular complications. Ann Surg 263: 1138–1142
21. Sjöström L, Peltonen M, Jacobson P, et al (2014) Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311: 2297–2304
22. Johnson BL, Blackhurst DW, Latham BB, et al (2013) Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 216: 545–556
23. Maggard-Gibbons M, Maglione M, Livhits M, et al (2013) Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA 309: 2250–2261
24. Mingrone G, Panunzi S, De Gaetano A, et al (2015) Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386(9997): 964–973
25. Schauer PR, Bhatt DL, Kirwan JP, et al (2017) Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 376: 641–651
26. Cummings DE, Arterburn DE, Westbrook EO, et al (2016) Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSS-ROADS randomised controlled trial. Diabetologia 59: 945–953
27. Ikramuddin S, Korner J, Lee WJ, et al (2013) Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309: 2240–2249
28. Wentworth JM, Playfair J, Laurie C, et al (2014) Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol 2: 545–552
29. Buse JB, Caprio S, Cefalu WT, et al (2009) How do we define cure of diabetes? Diabetes Care 32: 2133–2135
30. Panunzi S, De Gaetano A, Carnicelli A, Mingrone G (2015) Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg 261: 459–467
31. Müller-Stich BP, Senft JD, Warschkow R, et al (2015) Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg 261: 421–429
32. Haskins IN, Corcelles R, Froylich D, et al (2017) Primary inadequate weight loss after Roux-en-y gastric bypass is not associated with poor cardiovascular or metabolic outcomes: experience from a single institution. Obes Surg. 27: 676–680
33. Rubino F, Nathan DM, Eckel RH, et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39: 861–877
34. Müller-Stich BP, Fischer L, Kenngott HG, et al (2013) Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization – results of a prospective cohort study (DiaSurg 1 study). Ann Surg 258: 760–765
35. Billeter AT, Vittas S, Israel B, et al (2017) Gastric bypass simultaneously improves adipose tissue function and insulin-dependent type 2 diabetes mellitus. Langenbecks Arch Surg Jul 9. doi: 10.1007/s00423-017-1601-x [Epub ahead of print]
36. Billeter AT, Kopf S, Zeier M, et al (2016) Renal function in type 2 diabetes following gastric bypass. Dtsch Ärztebl Int 113: 827–833
37. Billeter AT, Probst P, Fischer L, et al (2015) Risk of malnutrition, trace metal, and vitamin deficiency post Roux-en-y gastric bypass-a prospective study of 20 patients with BMI <35 kg/m. Obes Surg 25: 2125-2134
38. Müller-Stich BP, Billeter AT, Fleming T, et al (2014) Nitrosative stress but not glycemic parameters correlate with improved neuropathy in nonseverely obese diabetic patients after Roux-Y gastric bypass. Surg Obes Relat Dis 11: 847–854
39. Kenngott HG, Clemens G, Gondan M, et al (2013) DiaSurg 2 trial--surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial – DRKS00004550. Trials 14: 183

40. van Dijk PR, Kramer A, Logtenberg SJ, et al (2015) Incidence of renal replacement therapy for diabetic nephropathy in the Netherlands: Dutch diabetes estimates (DUDE)-3. BMJ Open 5(1): e005624
41. Gross JL, de Azevedo MJ, Silveiro SP, et al (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28: 164–176
42. Molitch ME, DeFronzo RA, Franz MJ, et al (2004)Nephropathy in diabetes. Diabetes Care 27 (Suppl 1): S79–83
43. Molitch ME, DeFronzo RA, Franz MJ, et al (2003) Diabetic nephropathy. Diabetes Care 26 (Suppl 1): S94–98
44. Keane WF, Brenner BM, de Zeeuw D, et al ()The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney international. Apr 2003;63(4):1499-1507.
45. Caramori ML, Fioretto P, Mauer M (2000) The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 49: 1399–1408
46. Dyck PJ, Kratz KM, Karnes JL, et al (1993) The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43: 817–824
47. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559
48. Group AC, Patel A, MacMahon S, et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572
49. Billeter AT Probst P, Eichel S, et al (2017) Meta-analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. Br J Surg
50. Rutkowski JM, Wang ZV, Park AS, et al (2013) Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol 24: 268–282
51. Sharma K, Ramachandrarao S, Qiu G, et al (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645–1656
52. Hidmark A, Fleming T, Vittas S, et al (2014) A new paradigm to understand and treat diabetic neuropathy. Exp Clin Endocrinol Diabetes 122: 201–207
53. Dziemidok P, Szczesniak G, Kostrzewa-Zablocka E, et al (2012) Current glycaemic control has no impact on the advancement of diabetic neuropathy. Ann Agricult Environm Med 19: 742–745
54. Callaghan BC, Little AA, Feldman EL, Hughes RA (2012) Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 6: CD007543
55. Vincent AM, Callaghan BC, Smith AL, Feldman EL (2011) Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nature Rev Neurol 7: 573–583
56. Finucane TE (2010) Diabetic polyneuropathy and glucose control. JAMA 303: 420–421
57. Davies M, Brophy S, Williams R, Taylor A (2006) The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 29: 1518–1522
58. Partanen J, Niskanen L, Lehtinen J, et al (1995) Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 89–94
59. Obrosova IG, Drel VR, Oltman CL, et al (2007) Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. American journal of physiology. Endocrinol Metabol 293: E1645–1655
60. Obrosova IG, Mabley JG, Zsengeller Z, et al (2005) Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 19: 401–403
61. Pop-Busui R, Stevens MJ, Raffel DM, et al (2013) Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia 56: 1835–1844
62. Kasznicki J, Kosmalski M, Sliwinska A, et al (2012) Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep 39: 8669–8678
63. Russell JW, Berent-Spillson A, Vincent AM, et al (2008) Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis 30: 420–429
64. Du Y, Heidemann C, Schaffrath Rosario A, et al (2015) Changes in diabetes care indicators: findings from German National Health Interview and Examination Surveys 1997–1999 and 2008–2011. BMJ Open Diabetes Res Care 3(1): e000135
65. Banks J, Adams ST, Laughlan K, et al (2015) Roux-en-Y gastric bypass could slow progression of retinopathy in type 2 diabetes: a pilot study. Obes Surg 25: 777–781
66. Retnakaran R, Cull CA, Thorne KI, Group US (2006) Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55: 1832–1839
67. Sjöström L, Peltonen M, Jacobson P, et al (2012) Bariatric surgery and long-term cardiovascular events. JAMA 307: 56–65
68. Arterburn DE, Courcoulas AP (2014) Bariatric surgery for obesity and metabolic conditions in adults. Br Med J 349: g3961
69. Sovik TT, Aasheim ET, Taha O, et al (2011) Weight loss, cardiovascular risk factors, and quality of life after gastric bypass and duodenal switch: a randomized trial. Ann Intern Med 155: 281–291
70. Adams TD, Gress RE, Smith SC, et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357: 753–761
71. Costanzo P, Cleland JG, Pellicori P, et al (2015) The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Intern Med 162: 610–618
72. Tobias DK, Pan A, Jackson CL, et al (2014) Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med 370: 233–244
73. Thomas G, Khunti K, Curcin V, et al (2014) Obesity paradox in people newly diagnosed with type 2 diabetes with and without prior cardiovascular disease. Diabetes Obes Metabol 16: 317–325
74. Sharma AM, Kushner RF (2009) A proposed clinical staging system for obesity. Int J Obes 33: 289–295
75. Schauer PR, Nor Hanipah Z, Rubino F (2017) Metabolic surgery for treating type 2 diabetes mellitus: Now supported by the world's leading diabetes organizations. Cleveland Clin J Med 84 (7 Suppl 1): S47–S56